

Luigi Francesco Iannone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903388/publications.pdf>

Version: 2024-02-01

29
papers

695
citations

566801

15
h-index

580395

25
g-index

30
all docs

30
docs citations

30
times ranked

853
citing authors

#	ARTICLE	IF	CITATIONS
1	Microbiota-gut brain axis involvement in neuropsychiatric disorders. Expert Review of Neurotherapeutics, 2019, 19, 1037-1050.	1.4	116
2	Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. Frontiers in Neurology, 2018, 9, 1067.	1.1	60
3	Can we “seize” the gut microbiota to treat epilepsy?. Neuroscience and Biobehavioral Reviews, 2019, 107, 750-764.	2.9	60
4	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Current Medical Research and Opinion, 2020, 36, 1457-1463.	0.9	40
5	Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE, 2020, 15, e0241575.	1.1	38
6	First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. Epilepsia, 2021, 62, 529-541.	2.6	35
7	Pharmacology of Cenobamate: Mechanism of Action, Pharmacokinetics, Drug-Drug Interactions and Tolerability. CNS Drugs, 2021, 35, 609-618.	2.7	34
8	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Frontiers in Pharmacology, 2021, 12, 684638.	1.6	33
9	Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs, 2022, 36, 191-202.	2.7	32
10	The potential role of interventions impacting on gut-microbiota in epilepsy. Expert Review of Clinical Pharmacology, 2020, 13, 423-435.	1.3	25
11	Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. European Journal of Neurology, 2022, 29, 1505-1513.	1.7	25
12	Clinically relevant drug interactions between statins and antidepressants. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 227-239.	0.7	24
13	Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: A case series and literature review. Dermatologic Therapy, 2019, 32, e12748.	0.8	23
14	Results From an Italian Expanded Access Program on Cannabidiol Treatment in Highly Refractory Dravet Syndrome and Lennox-Gastaut Syndrome. Frontiers in Neurology, 2021, 12, 673135.	1.1	23
15	The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a “real world” context: focus on temporal lobe epilepsy. Journal of the Neurological Sciences, 2020, 415, 116903.	0.3	18
16	Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia, 2022, 42, 1323-1330.	1.8	18
17	Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. Gastric Cancer, 2021, 24, 765-779.	2.7	12
18	Status epilepticus in pregnancy: a literature review and a protocol proposal. Expert Review of Neurotherapeutics, 2022, 22, 301-312.	1.4	12

#	ARTICLE	IF	CITATIONS
19	The microbiota-gut-brain axis and epilepsy from a multidisciplinary perspective: Clinical evidence and technological solutions for improvement of in vitro preclinical models. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	3.9	10
20	Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). <i>PLoS ONE</i> , 2018, 13, e0205134.	1.1	9
21	Renal denervation for resistant hypertension. <i>The Cochrane Library</i> , 2021, 2021, CD011499.	1.5	9
22	A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report. <i>Current Drug Safety</i> , 2020, 15, 69-72.	0.3	7
23	Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE). <i>Epilepsy and Behavior</i> , 2021, 116, 107804.	0.9	7
24	Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 25-39.	0.9	6
25	Emerging Pharmacological Treatments for Migraine in the Pediatric Population. <i>Life</i> , 2022, 12, 536.	1.1	6
26	Management of status epilepticus in patients with liver or kidney disease: a narrative review. <i>Expert Review of Neurotherapeutics</i> , 2020, 21, 1-14.	1.4	4
27	Assessing knowledge and attitudes toward epilepsy among schoolteachers and students: Implications for inclusion and safety in the educational system. <i>PLoS ONE</i> , 2021, 16, e0249681.	1.1	4
28	Neuronal and non-neuronal TRPA1 as therapeutic targets for pain and headache relief. <i>Temperature</i> , 2023, 10, 50-66.	1.7	3
29	Gut microbiota and psychogenic non-epileptic seizures: i can feel it in the belly. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1165-1165.	1.4	2